Moleculin Biotech Inc - ESG Rating & Company Profile powered by AI
If you work at Moleculin Biotech Inc and you wish to use your ESG aseessment, please contact us. The report of Moleculin Biotech Inc leverages data points from across the internet as well as from public documents by Moleculin Biotech Inc. This webpage of Moleculin Biotech Inc was assembled by All Street Sevva using leading NLP.
Moleculin Biotech Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Moleculin Biotech Inc | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Moleculin Biotech Inc have an accelerator or VC vehicle to help deliver innovation?
Does Moleculin Biotech Inc disclose current and historical energy intensity?
Does Moleculin Biotech Inc report the average age of the workforce?
Does Moleculin Biotech Inc reference operational or capital allocation in relation to climate change?
Does Moleculin Biotech Inc disclose its ethnicity pay gap?
Does Moleculin Biotech Inc disclose cybersecurity risks?
Does Moleculin Biotech Inc offer flexible work?
Does Moleculin Biotech Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Moleculin Biotech Inc disclose the number of employees in R&D functions?
Does Moleculin Biotech Inc conduct supply chain audits?
Does Moleculin Biotech Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Moleculin Biotech Inc conduct 360 degree staff reviews?
Does Moleculin Biotech Inc disclose the individual responsible for D&I?
Does Moleculin Biotech Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Moleculin Biotech Inc disclose current and / or historical scope 2 emissions?
Does Moleculin Biotech Inc disclose water use targets?
Does Moleculin Biotech Inc have careers partnerships with academic institutions?
Did Moleculin Biotech Inc have a product recall in the last two years?
Does Moleculin Biotech Inc disclose incidents of discrimination?
Does Moleculin Biotech Inc allow for Work Councils/Collective Agreements to be formed?
Has Moleculin Biotech Inc issued a profit warning in the past 24 months?
Does Moleculin Biotech Inc disclose parental leave metrics?
Does Moleculin Biotech Inc disclose climate scenario or pathway analysis?
Does Moleculin Biotech Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Moleculin Biotech Inc disclose the pay ratio of women to men?
Does Moleculin Biotech Inc support suppliers with sustainability related research and development?
Does Moleculin Biotech Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Moleculin Biotech Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Moleculin Biotech Inc involved in embryonic stem cell research?
Does Moleculin Biotech Inc disclose GHG and Air Emissions intensity?
Does Moleculin Biotech Inc disclose its waste policy?
Does Moleculin Biotech Inc report according to TCFD requirements?
Does Moleculin Biotech Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Moleculin Biotech Inc disclose energy use targets?
Does Moleculin Biotech Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Moleculin Biotech Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Moleculin Biotech Inc
These potential risks are based on the size, segment and geographies of the company.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.